After being informed about the study and potential risks, all patients giving written informed consent will undergo a risk-stratified dose of treatment (radiation dose and chemotherapy number of cycles) based on predefined clinical and biological biomarkers for anal squamous cell carcinoma (SCC). Radiotherapy will be delivered on the MR-Linac for image-guided-radiation therapy (IGRT). Patients will be followed for up to 5 years after radiotherapy and be required to complete questionnaires and clinic visits. Patients have the option to complete blood and tissue samples during the study.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients with pathologically proven diagnosis of anal SCC. This may include tumors of non-keratinizing histology such as basoloid or cloacogenic histology. Individuals with squamous cell carcinoma of the anal margin are eligible.
Clinical stage T1-4 N0-1 M0 (the Union for International Cancer Control (UICC) / the American Joint Committee on Cancer (AJCC) 8th Ed)
Patients must be eligible for definitive RT or CRT
Must be ≥ 18 years of age
Must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
You may not be if
Previous chemotherapy, RT or curative-intent surgical treatment (i.e. APR) for anal cancer.
Any previous RT to the abdomino-pelvic region that would result in overlap of RT volume for the current study.
